iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Conference, being held virtually on Tuesday, January 12, 2021 at 9:10 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
Amber Fennell, Paul Kidwell
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Juniper Systems Limited Releases New Uinta Software Worldwide26.1.2021 05:16:00 CET | Press release
Summary: Uinta™, powerful data collection software from Juniper Systems Limited, is now available throughout EMEA and India, for field crews in asset management, mapping, natural resources, and other industries. BIRMINGHAM, United Kingdom, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Juniper Systems Limited, a manufacturer of rugged handheld computers and GNSS receivers, introduces Uinta™, powerful data collection software for field crews using Microsoft® Windows 10 OS on tablets, who require detailed forms, maps and customisation. Now available throughout Europe, the Middle East, Africa (EMEA), and India, Uinta (yü-ӘN-tah) offers data collection tools such as detailed mapping with points, lines, and areas, form-based notes, and flexibility, delivering a high level of customisation specific to an organisation’s needs. ‘Historically, Juniper Systems has manufactured rugged computer hardware. We’re excited now to offer user-friendly software for many industries, including mapping and asset manageme
PRESS RELEASE: NACON: Q3 2020/21 Sales: 48.7 M€, + 20.3%25.1.2021 17:45:00 CET | Press release
Press release Lesquin, 25 January 2021 17:45hrs Q3 2020/21 Sales: 48.7 M€, + 20.3% ·Gaming Accessories : 32.5 M€, + 59% ·Games Back catalogue : 6.9 M€, + 216% ·Confirmation of annual targets IFRS – M€ Sales 2020/2021 2019/2020 Change 1st Quarter 38.0 30.5 + 24.5% 2nd Quarter 48.6 33.2 + 46.4% 3rd Quarter (1) Games Accessories Others (2) 48.7 13.8 32.5 2.3 40.5 17.2 20.5 2.8 + 20.3% - 19.7% + 58.7% - 16.3% Cumulative 31 December (9 months) Games Accessories Others (2) 135.3 46.6 84.1 4.5 104.2 55.0 44.1 5.1 + 29.9% - 15.1% + 90.5% - 10.4% (1) Non audited data (2)Mobile and Audio sales Further strong growth in Q3 2020/21: +20.3% In Q3 2020/21 (1 October to 31 December 2020), Nacon posted 48.7 M€ sales up 20.3%, driven by the performance of RIG® headsets and increased back catalogue sales. GAMES Due to Q3 publishing releases limited to just two new games targetting profitable but narrow niches (Monster Truck®, Handball 21), sales were down by 19.7%. The share of digital sales grew further
PRESS RELEASE: BIGBEN: Cumulative 9 month Sales 2020/21: 223.1 M€ (+ 5%)25.1.2021 17:45:00 CET | Press release
Press release Lesquin, 25 January 2021 17:45hrs Cumulative 9 month Sales 2020/21: 223.1 M€ (+ 5%) Q3 Sales showing growth hallmarked by: ·the further momentum of Nacon Gaming ·The limited impact of the 2 nd lockdown in Audio/Telco IFRS – M€ Sales 2020/2021 2019/2020 Change 1st Quarter (April, May, June) Nacon Gaming Bigben Audio / Telco 55.2 38.0 17.2 58.6 30.5 28.1 - 5.8% + 24.5% - 38.7%2nd Quarter (July, Aug., Sept.) Nacon Gaming Bigben Audio / Telco80.6 48.6 32.068.5 33.2 35,3+ 17.7% + 46.4% - 9.4%3rd Quarter (October, Nov., Dec.) (1) Nacon Gaming Bigben Audio / Telco87.3 48.6 38.785.4 40.5 44.9+ 2.3% + 20.3% - 13.9%Cumulative 9 month (Apr-Dec 2020) Nacon Gaming Bigben Audio / Telco223.1 135.3 87.8212.4 104.2 108.2+ 5.0% + 29.9% - 18.9% (1) Non audited data Sales up 2.3% in Q3 2020/21 In Q3 2020/2021 (from October 1 to December 31, 2020), Bigben posted 87.3 M€ sales up 2.3%, driven by the momentum of Nacon Gaming, while the recovery of Audio/Telco was slowed down by the 2nd lockdown
Fire Departments Can Improve Fire Safety with Free Analytics Platform from Verisk25.1.2021 17:03:22 CET | Press release
Verisk’s Mitigate Website Provides Benchmarks, Maps, and Dashboard of ISO Public Protection Classification (PPC®) Data to Fire Departments, Community Leaders Jersey City, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Fire departments across the United States can now access advanced analytic and visualization tools to help improve their local fire protection at no charge. Verisk (Nasdaq:VRSK), a leading data analytics provider, is offering complimentary access to ISO Mitigate (https://www.isomitigation.com/mitigate/ https://www.isomitigation.com/mitigate/), a new, interactive web platform that offers data-driven analytics to support strategic planning. Verisk’s Mitigate platform allows fire chiefs and local officials to benchmark their community’s https://www.isomitigation.com/ppc/ Public Protection Classification (PPC®) score (PPC), visualize their performance, and make data-driven decisions about investing in fire safety and preparedness. The PPC program, which is used by the vast majority of
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER25.1.2021 16:20:00 CET | Press release
Bid procedure, 2021-01-27CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-07-27 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-01-18 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-01-27Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
Vertex Acquires Edge Computing Company Tellutax to Extend its Global Leadership in Tax Technology25.1.2021 15:55:09 CET | Press release
KING OF PRUSSIA, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading provider of tax technology and services, announced that it has acquired Tellutax, a Portland-based edge computing technology startup. Financial terms of the transaction were not disclosed. Tellutax designs edge-based technology utilizing a container architecture, which enables customers to deliver tax solutions seamlessly at the point of need with increased scalability and simplified management. “We believe Tellutax edge technology will extend our leadership in the enterprise market and accelerate our ecosystem expansion into next generation payment and IoT platforms,” said Vertex president and CEO David DeStefano. “This acquisition furthers our technology roadmap and hybrid cloud strategy, enabling us to serve customers in an increasingly hyper-connected environment.” Tellutax was founded in 2018 by two accomplished executives in tax automation software. Tellutax C
Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction25.1.2021 14:00:00 CET | Press release
PRESS RELEASE January 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona’s ion channel expertise for the treatment of movement disorders. Saniona previously announced the planned acquisition and its ownership stake in December 2020. “Saniona has developed a robust, proprietary drug discovery engine focused on ion channels, a rare scientifically validated drug class that remains significantly untapped,” said Jørgen Drejer, Chief Scientific Officer of Saniona. “It is gratifying to see our ion channel programs create value, and the funding that Saniona received from th